Categories: News

Outset Medical Reports Second Quarter 2021 Financial Results

2021 Revenue Guidance Range Updated to $97 million to $100 million

SAN JOSE, Calif.–(BUSINESS WIRE)–Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2021.

Recent Highlights

  • Recorded net revenue of $25.2 million in the second quarter of 2021, a 115% increase compared to $11.7 million in the second quarter of 2020
  • Achieved gross margin of 4.2% in the second quarter of 2021 compared to (40.6%) in the second quarter of 2020
  • Appointed former Amazon AWS Health AI executive Jean-Olivier Racine as Chief Technology Officer
  • Appointed Edwards Life Sciences Corporate VP Katie Szyman to the Board of Directors
  • Announced several multi-year sales agreements with innovative dialysis care providers to drive home hemodialysis adoption with Tablo

“In the first half of 2021, we delivered best-in-class revenue growth and steady gross margin improvement driven by a team that is dedicated to, and united around, transforming the dialysis experience for patients and providers,” said Leslie Trigg, President and Chief Executive Officer. “With new home console bookings up substantially in the second quarter, and both current and new customers purchasing Tablo for acute use, our integrated commercial strategy is working as expected. We remain confident in our ability to execute on each of our key strategic initiatives for 2021 and in our long-term growth prospects.”

Second Quarter 2021 Financial Results

Revenue for the second quarter of 2021 was $25.2 million, representing an increase of 115% compared to $11.7 million in the second quarter of 2020. Product revenue for the second quarter of 2021 was $20.6 million, representing an increase of 113% compared to $9.7 million in the second quarter of 2020. Service and other revenue for the second quarter of 2021 was $4.6 million, representing an increase of 124% compared to $2.0 million in the second quarter of 2020.

Total gross profit for the second quarter of 2021 was $1.0 million, compared to a gross loss of ($4.8) million for the second quarter of 2020. Total gross margin for the second quarter of 2021 was 4.2%, compared to (40.6%) in the second quarter of 2020. Product gross loss for the second quarter of 2021 was ($1.4) million, compared to ($5.6) million of product gross loss in the second quarter of 2020. Product gross margin for the second quarter of 2021 was (7.0%), compared to (57.7%) in the second quarter of 2020. Service and other gross profit for the second quarter of 2021 was $2.5 million, compared to $0.8 million of service and other gross profit in the second quarter of 2020. Service and other gross margin for the second quarter of 2021 was 54.5%, compared to 40.6% in the second quarter of 2020.

Operating expenses for the second quarter of 2021 were $31.0 million, including research and development (R&D) expenses of $8.0 million, sales and marketing (S&M) expenses of $13.2 million, and general and administrative (G&A) expenses of $9.7 million. This compared to operating expenses of $20.1 million, including R&D expenses of $6.1 million, S&M expenses of $9.2 million, and G&A expenses of $4.8 million in the second quarter of 2020.

Excluding stock-based compensation expense, non-GAAP operating expenses for the second quarter of 2021 were $27.1 million, including R&D expenses of $7.4 million, S&M expenses of $12.2 million, and G&A expenses of $7.5 million.

Second quarter 2021 net loss was ($30.2) million, or ($0.66) per share, compared to net loss of ($26.5) million, or ($4.58) per share, for the same period in 2020. On a non-GAAP basis, net loss for the second quarter of 2021 was ($26.3) million, or ($0.57) per share, compared to non-GAAP net loss of ($25.8) million, or ($4.46) per share for the same period in 2020.

Total cash, including restricted cash, cash equivalents and short-term investments, was $429.5 million as of June 30, 2021. The Company generated approximately $149.1 million in net proceeds from its April 2021 public offering.

Full Year 2021 Financial Guidance

Outset projects revenue for the full year 2021 to range from $97 million to $100 million, which represents approximately 94% to 100% growth over the Company’s fiscal year 2020 revenue. This updated guidance compares to prior 2021 revenue guidance of $92 million to $97 million.

Webcast and Conference Call Details

Outset will host a conference call today, August 5, 2021, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its second quarter 2021 financial results. The dial-in numbers are (833) 614-1409 for domestic callers and (914) 987-7130 for international callers. The conference ID is 7927579. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non‐GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include stock-based compensation expense, as listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. Management has excluded the effects of this non-cash expense item in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, profitability and outlook, statements regarding the Company’s overall business strategy, plans and objectives of management, as well as the Company’s expectations regarding the continuing impact of the COVID-19 pandemic on the Company and its operations as well as the impact on its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Outset’s public filings with the Securities and Exchange Commission, including Outset’s latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Outset Medical, Inc.

Condensed Statements of Operations

(in thousands, except per share amounts)

(unaudited)

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

20,628

 

 

 

$

9,697

 

 

 

$

38,838

 

 

 

$

15,623

 

 

Service and other revenue

 

 

4,588

 

 

 

 

2,045

 

 

 

 

9,294

 

 

 

 

3,309

 

 

Total revenue

 

 

25,216

 

 

 

 

11,742

 

 

 

 

48,132

 

 

 

 

18,932

 

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue (2)

 

 

22,077

 

 

 

 

15,291

 

 

 

 

42,654

 

 

 

 

24,853

 

 

Cost of service and other revenue

 

 

2,087

 

 

 

 

1,215

 

 

 

 

4,137

 

 

 

 

2,407

 

 

Total cost of revenue

 

 

24,164

 

 

 

 

16,506

 

 

 

 

46,791

 

 

 

 

27,260

 

 

Gross profit (1)

 

 

1,052

 

 

 

 

(4,764

)

 

 

 

1,341

 

 

 

 

(8,328

)

 

Gross margin (1)

 

 

4.2

 

%

 

 

(40.6

)

%

 

 

2.8

 

%

 

 

(44.0

)

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (2)

 

 

8,032

 

 

 

 

6,053

 

 

 

 

15,602

 

 

 

 

11,891

 

 

Sales and marketing (2)

 

 

13,204

 

 

 

 

9,244

 

 

 

 

26,353

 

 

 

 

16,526

 

 

General and administrative (2)

 

 

9,722

 

 

 

 

4,848

 

 

 

 

18,968

 

 

 

 

8,374

 

 

Total operating expenses

 

 

30,958

 

 

 

 

20,145

 

 

 

 

60,923

 

 

 

 

36,791

 

 

Loss from operations

 

 

(29,906

)

 

 

 

(24,909

)

 

 

 

(59,582

)

 

 

 

(45,119

)

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income and other income, net

 

 

164

 

 

 

 

67

 

 

 

 

276

 

 

 

 

527

 

 

Interest expense

 

 

(431

)

 

 

 

(1,032

)

 

 

 

(853

)

 

 

 

(2,033

)

 

Change in fair value of redeemable convertible

preferred stock warrant liability

 

 

 

 

 

 

(631

)

 

 

 

 

 

 

 

(530

)

 

Loss before provision for income taxes

 

 

(30,173

)

 

 

 

(26,505

)

 

 

 

(60,159

)

 

 

 

(47,155

)

 

Provision for income taxes

 

 

35

 

 

 

 

 

 

 

 

74

 

 

 

 

 

 

Net loss

 

$

(30,208

)

 

 

$

(26,505

)

 

 

$

(60,233

)

 

 

$

(47,155

)

 

Net loss attributable to common stockholders,

basic and diluted (3)

 

$

(30,208

)

 

 

$

(26,505

)

 

 

$

(60,233

)

 

 

$

(4,987

)

 

Net loss per share attributable to common stockholders,

basic and diluted

 

$

(0.66

)

 

 

$

(4.58

)

 

 

$

(1.36

)

 

 

$

(0.98

)

 

Weighted-average shares used in computing net loss per share

attributable to common stockholders, basic and diluted

 

 

45,680

 

 

 

 

5,784

 

 

 

 

44,228

 

 

 

 

5,086

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Gross profit and gross margin by source consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

(1,449

)

 

 

$

(5,594

)

 

 

$

(3,816

)

 

 

$

(9,230

)

 

Service and other revenue

 

 

2,501

 

 

 

 

830

 

 

 

 

5,157

 

 

 

 

902

 

 

Total gross profit

 

$

1,052

 

 

 

$

(4,764

)

 

 

$

1,341

 

 

 

$

(8,328

)

 

Gross margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

 

(7.0

)

%

 

 

(57.7

)

%

 

 

(9.8

)

%

 

 

(59.1

)

%

Service and other revenue

 

 

54.5

 

%

 

 

40.6

 

%

 

 

55.5

 

%

 

 

27.3

 

%

Total gross margin

 

 

4.2

 

%

 

 

(40.6

)

%

 

 

2.8

 

%

 

 

(44.0

)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2) Include stock-based compensation expenses as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

Cost of revenue

 

$

62

 

 

 

$

20

 

 

 

$

137

 

 

 

$

39

 

 

Research and development

 

 

643

 

 

 

 

134

 

 

 

 

1,808

 

 

 

 

252

 

 

Sales and marketing

 

 

1,052

 

 

 

 

101

 

 

 

 

2,794

 

 

 

 

183

 

 

General and administrative

 

 

2,180

 

 

 

 

428

 

 

 

 

5,050

 

 

 

 

789

 

 

Total stock-based compensation expenses

 

$

3,937

 

 

 

$

683

 

 

 

$

9,789

 

 

 

$

1,263

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3) A reconciliation of the net loss to net loss attributable to common stockholders is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

Net loss

 

$

(30,208

)

 

 

$

(26,505

)

 

 

$

(60,233

)

 

 

$

(47,155

)

 

Adjustment to redemption value on redeemable convertible

preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(362

)

 

Deemed dividend on settlement of accrued dividend*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

42,530

 

 

Net loss attributable to common stockholders, basic and diluted

 

$

(30,208

)

 

 

$

(26,505

)

 

 

$

(60,233

)

 

 

$

(4,987

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Deemed dividend on settlement of accrued dividend arose as a result of the terms and conditions associated with the Company’s redeemable convertible preferred stock outstanding prior to the Company’s initial public offering (“IPO”). These terms and conditions were described in the Company’s previous SEC filings, including the 424(b) prospectus filed on September 16, 2020 in connection with the IPO.

 

 

 

 

 

 

 

 

Outset Medical, Inc.

Condensed Balance Sheets

(in thousands, except per share amounts)

 

 

June 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

274,274

 

 

$

294,972

 

Short-term investments

 

 

121,934

 

 

 

19,898

 

Accounts receivable, net

 

 

16,411

 

 

 

6,468

 

Inventories

 

 

28,882

 

 

 

18,384

 

Prepaid expenses and other current assets

 

 

6,459

 

 

 

6,189

 

Total current assets

 

 

447,960

 

 

 

345,911

 

Restricted cash

 

 

33,311

 

 

 

33,311

 

Property and equipment, net

 

 

15,275

 

 

 

14,998

 

Operating lease right-of-use assets

 

 

7,752

 

 

 

8,253

 

Other assets

 

 

515

 

 

 

1,356

 

Total assets

 

$

504,813

 

 

$

403,829

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,364

 

 

$

4,948

 

Accrued compensation and related benefits

 

 

15,308

 

 

 

16,845

 

Accrued expenses and other current liabilities

 

 

9,256

 

 

 

7,903

 

Accrued warranty liability

 

 

3,073

 

 

 

2,913

 

Deferred revenue, current

 

 

4,373

 

 

 

3,201

 

Operating lease liabilities, current

 

 

1,069

 

 

 

882

 

Total current liabilities

 

 

35,443

 

 

 

36,692

 

Accrued interest, noncurrent

 

 

479

 

 

 

240

 

Deferred revenue, noncurrent

 

 

515

 

 

 

570

 

Operating lease liabilities, noncurrent

 

 

7,496

 

 

 

8,044

 

Term loan, noncurrent

 

 

29,718

 

 

 

29,674

 

Total liabilities

 

 

73,651

 

 

 

75,220

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of June 30, 2021 and December 31, 2020

 

 

 

 

 

 

Common stock, $0.001 par value; 300,000 shares authorized as of June 30, 2021 and December 31, 2020; 46,225 and 42,722 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively

 

 

46

 

 

 

43

 

Additional paid-in capital

 

 

985,436

 

 

 

822,624

 

Accumulated other comprehensive (loss) income

 

 

(28

)

 

 

1

 

Accumulated deficit

 

 

(554,292

)

 

 

(494,059

)

Total stockholders’ equity

 

 

431,162

 

 

 

328,609

 

Total liabilities and stockholders’ equity

 

$

504,813

 

 

$

403,829

 

Outset Medical, Inc.

Condensed Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

Net cash used in operating activities

 

$

(69,457

)

 

$

(44,059

)

Net cash (used in) provided by investing activities

 

 

(104,267

)

 

 

25,471

 

Net cash provided by financing activities

 

 

153,026

 

 

 

126,797

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(20,698

)

 

 

108,209

 

Cash, cash equivalents and restricted cash at beginning of the period

 

 

328,283

 

 

 

37,669

 

Cash, cash equivalents and restricted cash at end of the period (1)

 

$

307,585

 

 

$

145,878

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows:

 

 

 

 

 

June 30,

 

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

274,274

 

 

$

141,871

 

Restricted cash

 

 

33,311

 

 

 

4,007

 

Total cash, cash equivalents and restricted cash*

 

$

307,585

 

 

$

145,878

 

 

 

 

 

 

 

 

 

 

* The total cash, including restricted cash, cash equivalents and short-term investments as of June 30, 2021 was $429.5 million; compared to $148.4 million as of June 30, 2020.

 

 

 

Appendix A

Outset Medical, Inc.

Results of Operations – Non-GAAP

(in thousands, except per share amounts)

(unaudited)

Reconciliation between GAAP and non-GAAP net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

GAAP net loss per share to common stockholders, diluted

 

$

(0.66

)

 

 

$

(4.58

)

 

 

$

(1.36

)

 

 

$

(0.98

)

 

Stock-based compensation expense

 

 

0.09

 

 

 

 

0.12

 

 

 

 

0.22

 

 

 

 

0.25

 

 

Non-GAAP net loss per share to common stockholders,

diluted

 

$

(0.57

)

 

 

$

(4.46

)

 

 

$

(1.14

)

 

 

$

(0.73

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation between GAAP and non-GAAP net loss attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

GAAP net loss attributable to common stockholders, diluted

 

$

(30,208

)

 

 

$

(26,505

)

 

 

$

(60,233

)

 

 

$

(4,987

)

 

Stock-based compensation expense

 

 

3,937

 

 

 

 

683

 

 

 

 

9,789

 

 

 

 

1,263

 

 

Non-GAAP net loss attributable to common

stockholders, diluted

 

$

(26,271

)

 

 

$

(25,822

)

 

 

$

(50,444

)

 

 

$

(3,724

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation between GAAP and non-GAAP results of operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

GAAP gross profit

 

$

1,052

 

 

 

$

(4,764

)

 

 

$

1,341

 

 

 

$

(8,328

)

 

Stock-based compensation expense

 

 

62

 

 

 

 

20

 

 

 

 

137

 

 

 

 

39

 

 

Non-GAAP gross profit

 

$

1,114

 

 

 

$

(4,744

)

 

 

$

1,478

 

 

 

$

(8,289

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

 

4.2

 

%

 

 

(40.6

)

%

 

 

2.8

 

%

 

 

(44.0

)

%

Stock-based compensation expense

 

 

0.2

 

 

 

 

0.2

 

 

 

 

0.3

 

 

 

 

0.2

 

 

Non-GAAP gross margin

 

 

4.4

 

%

 

 

(40.4

)

%

 

 

3.1

 

%

 

 

(43.8

)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP research and development expense

 

$

8,032

 

 

 

$

6,053

 

 

 

$

15,602

 

 

 

$

11,891

 

 

Stock-based compensation expense

 

 

(643

)

 

 

 

(134

)

 

 

 

(1,808

)

 

 

 

(252

)

 

Non-GAAP research and development expense

 

$

7,389

 

 

 

$

5,919

 

 

 

$

13,794

 

 

 

$

11,639

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP sales and marketing expense

 

$

13,204

 

 

 

$

9,244

 

 

 

$

26,353

 

 

 

$

16,526

 

 

Stock-based compensation expense

 

 

(1,052

)

 

 

 

(101

)

 

 

 

(2,794

)

 

 

 

(183

)

 

Non-GAAP sales and marketing expense

 

$

12,152

 

 

 

$

9,143

 

 

 

$

23,559

 

 

 

$

16,343

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP general and administrative expense

 

$

9,722

 

 

 

$

4,848

 

 

 

$

18,968

 

 

 

$

8,374

 

 

Stock-based compensation expense

 

 

(2,180

)

 

 

 

(428

)

 

 

 

(5,050

)

 

 

 

(789

)

 

Non-GAAP general and administrative expense

 

$

7,542

 

 

 

$

4,420

 

 

 

$

13,918

 

 

 

$

7,585

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP total operating expense

 

$

30,958

 

 

 

$

20,145

 

 

 

$

60,923

 

 

 

$

36,791

 

 

Stock-based compensation expense

 

 

(3,875

)

 

 

 

(663

)

 

 

 

(9,652

)

 

 

 

(1,224

)

 

Non-GAAP total operating expense

 

$

27,083

 

 

 

$

19,482

 

 

 

$

51,271

 

 

 

$

35,567

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contacts

Investor Contact
Lynn Lewis or Brian Johnston

Gilmartin Group

investors@outsetmedical.com

Media Contact
Nicole Shannon

Director, Marketing Communications for Outset Medical

nshannon@outsetmedical.com

Staff

Recent Posts

Empatho Holdings Inc. Announces Litigation

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Empatho Holdings Inc. (the "Company") announces that…

36 mins ago

ZetrOZ Systems Marks Mid-Year with Presentations at Major Athletic and Military Medicine Conferences

Makers of the sam® wearable ultrasound unit present new research on the effectiveness of sustained…

3 hours ago

Veterinarians Putting Children First

Child care in the Veterinary IndustryBEND, OR / ACCESSWIRE / June 18, 2024 / Vet…

3 hours ago

Cosmo’s Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China

Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43)…

5 hours ago

Healing Realty Trust Closes First Tranche of Series A to Expand Clinic-Focused Portfolio for a New Generation of Medicine

Investment to fund acquisitions of three operating healthcare facilities in Texas, Ohio and Connecticut, totaling…

6 hours ago